Compile Data Set for Download or QSAR
Report error Found 169 Enz. Inhib. hit(s) with all data for entry = 11658
TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636877(US20230382889, Compound 11 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataKi:  0.130nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636903(US20230382889, Compound 47 | N-(4-(4-(2-(4,4-diflu...)
Affinity DataKi:  0.200nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636901(US20230382889, Compound 45 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataKi:  0.210nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636881(US20230382889, Compound 15 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataKi:  0.520nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636927(US20230382889, Compound 69 | N-(4-(4-(2-(4,4-diflu...)
Affinity DataKi:  0.530nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636926(US20230382889, Compound 68 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataKi:  0.820nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636871(US20230382889, Compound 5 | N-(4-(5-(6-(4,4-difluo...)
Affinity DataKi:  1.5nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636917(US20230382889, Compound 59 | N-(5-(4-(6-(4,4-diflu...)
Affinity DataIC50: 1.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636925(US20230382889, Compound 67 | N-(4-(4-(2-(4,4-diflu...)
Affinity DataKi:  1.70nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636907(US20230382889, Compound 51 | US20230382889, Compou...)
Affinity DataIC50: 2.40nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637003(US20230382889, Compound 144 | N-(4-(4-(6-(4,4-difl...)
Affinity DataIC50: 2.80nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636907(US20230382889, Compound 51 | US20230382889, Compou...)
Affinity DataIC50: 2.80nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636907(US20230382889, Compound 51 | US20230382889, Compou...)
Affinity DataIC50: 3.10nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636921(US20230382889, Compound 63 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataIC50: 3.40nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637019(US20230382889, Compound 158 | 2-(4,4-difluoropiper...)
Affinity DataIC50: 3.80nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637005(US20230382889, Compound 146 | 3-(4,4-difluoropiper...)
Affinity DataIC50: 4.40nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637021(US20230382889, Compound 160 | N-(4-(4-(2-(4,4-difl...)
Affinity DataIC50: 4.40nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636954(US20230382889, Compound 96 | N-(4-(1-(6-(4,4-diflu...)
Affinity DataIC50: 4.40nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636981(US20230382889, Compound 123 | N-(4-(4-(5- (cyclope...)
Affinity DataIC50: 4.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636890(US20230382889, Compound 25 | N-(4-(4-(5- (cyclopen...)
Affinity DataIC50: 4.70nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636941(US20230382889, Compound 84 | N-(4-(4-(1-(4,4-diflu...)
Affinity DataIC50: 5nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636874(US20230382889, Compound 8 | N-(4-(5-(6-(4,4-difluo...)
Affinity DataIC50: 5.10nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636947(US20230382889, Compound 90a | US20230382889, Compo...)
Affinity DataIC50: 5.20nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637002(US20230382889, Compound 143 | N-(4-(4-(6-(4,4-difl...)
Affinity DataIC50: 5.5nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636947(US20230382889, Compound 90a | US20230382889, Compo...)
Affinity DataIC50: 5.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636927(US20230382889, Compound 69 | N-(4-(4-(2-(4,4-diflu...)
Affinity DataIC50: 6nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637010(US20230382889, Compound 150 | N-(4-(4-(6-(cyclpent...)
Affinity DataIC50: 6nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636996(US20230382889, Compound 137 | N-(4-(4-(6-(4,4-difl...)
Affinity DataIC50: 6.30nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636995(US20230382889, Compound 136 | N-(4-(4-(5-fluoro-6-...)
Affinity DataIC50: 6.5nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636918(US20230382889, Compound 60 | N-(4-(4-(6-(3,3-diflu...)
Affinity DataIC50: 6.5nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636901(US20230382889, Compound 45 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataIC50: 6.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636881(US20230382889, Compound 15 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataIC50: 6.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636871(US20230382889, Compound 5 | N-(4-(5-(6-(4,4-difluo...)
Affinity DataIC50: 6.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636932(US20230382889, Compound 75 | N-(3-(azepan-1-yl)-4-...)
Affinity DataIC50: 7.10nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM637017(US20230382889, Compound 154 | N-(4-(4-(5-fluoro-6-...)
Affinity DataIC50: 7.10nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636879(US20230382889, Compound 13 | N-(4-(4-(3-((3,3-difl...)
Affinity DataIC50: 7.20nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636906(US20230382889, Compound 50 | N-(4-(4-(2-(4,4-diflu...)
Affinity DataIC50: 7.20nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636982(US20230382889, Compound 124 | N-(4-(4-(6-(4,4-difl...)
Affinity DataIC50: 7.30nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636919(US20230382889, Compound 61 | N-(4-(4-(6-(3,3-diflu...)
Affinity DataIC50: 8nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636957(US20230382889, Compound 99 | N-(4-(4-(2-(3-azabicy...)
Affinity DataIC50: 8.10nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636941(US20230382889, Compound 84 | N-(4-(4-(1-(4,4-diflu...)
Affinity DataIC50: 8.20nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636912(US20230382889, Compound 54 | N-(4-(4-(6-morpholino...)
Affinity DataIC50: 8.30nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636991(US20230382889, Compound 132 | N-(tert-butyl)-5-(1-...)
Affinity DataIC50: 8.5nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636923(US20230382889, Compound 65 | N-(4-(1-(3-(4,4-diflu...)
Affinity DataIC50: 8.60nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636884(US20230382889, Compound 18 | N-(4-(4-(6-(4,4-diflu...)
Affinity DataIC50: 8.70nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636875(US20230382889, Compound 9 | N-(4-(5-(6-(4,4-difluo...)
Affinity DataKi:  8.70nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636967(US20230382889, Compound 109 | N-(4-(4-(2-(cyclopen...)
Affinity DataIC50: 8.80nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636839(US20230382889, Compound 2 | N-(4-(5-(6-morpholinop...)
Affinity DataKi:  8.90nMAssay Description:Compound binding kinetics parameters (kon and koff) were determined by the method of global progress curve analysis (GPCA). KIF18A (0.25 nM) was incu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636983(US20230382889, Compound 125 | N-(4-(4-(5-(cyclopen...)
Affinity DataIC50: 9nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

TargetKinesin-like protein KIF18A(Human)
Volastra Therapeutics

US Patent
LigandPNGBDBM636902(US20230382889, Compound 46 | N-(5-(4-(6-(4,4-diflu...)
Affinity DataIC50: 9.10nMAssay Description:Test compounds were plated in a 3x dilution scheme in a 384-well plate. Assay buffer: 80 mM PIPES (pH 6.9), 1 mM MgCl2, 75 mM KCl, 1 mM EGTA, 1 mM DT...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/19/2024
Entry Details
US Patent

Displayed 1 to 50 (of 169 total ) | Next | Last >>
Jump to: